90Y玻璃微球经动脉放射性栓塞治疗肝细胞癌:基于剂量-毒性关系优化治疗
本研究为单臂回顾性研究,收集中晚期肝细胞癌患者接受90Y玻璃微球经动脉放射性栓塞治疗的数据,注射始终为肺叶性。通过99mTc-MAA SPECT/CT预处理剂量学分析,发现全非肿瘤肝平均吸收剂量与肝失代偿相关(OR=4.24),基线胆红素>1.1 mg/dL为更显著风险因素(OR=6.35)。NTCP分析显示胆红素>1.1 mg/dL者在50 Gy、<1.1 mg/dL者在90 Gy时肝失代偿风险为15%。结论认为优化治疗应瞄准全非肿瘤肝平均吸收剂量50 Gy/90 Gy(分别对应胆红素高于/低于1.1 mg/dL)。
要点
- 全非肿瘤肝平均吸收剂量与肝失代偿相关,OR=4.24。
- 基线胆红素>1.1 mg/dL是更显著风险因素,OR=6.35。
- 胆红素>1.1 mg/dL者50 Gy、<1.1 mg/dL者90 Gy时肝失代偿风险15%。
核心结论
- 鉴于99mTc-MAA对病灶吸收剂量预测准确性低,参考时间后4天肺叶性注射90Y玻璃微球的优化TARE应瞄准全非肿瘤肝平均吸收剂量:基线胆红素高于1.1 mg/dL者为50 Gy,低于1.1 mg/dL者为90 Gy。
研究设计与样本
- 单臂回顾性研究,收集中晚期肝细胞癌患者接受90Y玻璃微球治疗的数据,注射始终为肺叶性,即使双叶病变也避免单次治疗全肝。
- 引入三级肝失代偿定义,仅将需医疗干预的肝失代偿(LD type C,LDC)视为毒性。
- 报告LDC发生率、LDC与无LDC吸收剂量分布的ROC分析、正常组织并发症概率(NTCP)曲线及与毒性相关风险因素的单因素和多因素分析。
主要发现
- 定义6个月时间线以捕获所有治疗相关毒性事件。
- 既往TACE、门静脉瘤栓(PVTT) presence或范围及肿瘤模式(结节型 vs 浸润型)与TARE耐受性无关。
- 多因素分析中,全非肿瘤肝(包括未注射叶)平均吸收剂量为与肝失代偿相关的预后指标(OR=4.24)。
- 基线胆红素>1.1 mg/dL为第二个更显著风险因素(OR=6.35)。
- 以该胆红素切点分层的NTCP分析确定胆红素>1.1 mg/dL者在50 Gy、<1.1 mg/dL者在90 Gy时肝失代偿风险为15%,结果适用于参考时间后4天给予90Y玻璃微球。
关键数值与推荐
- 全非肿瘤肝平均吸收剂量与肝失代偿相关,OR=4.24。
- 基线胆红素>1.1 mg/dL与肝失代偿相关,OR=6.35。
- NTCP分析:胆红素>1.1 mg/dL者50 Gy时肝失代偿风险15%,胆红素<1.1 mg/dL者90 Gy时肝失代偿风险15%。
- 结果适用于参考时间后4天给予90Y玻璃微球。
临床怎么用
- 作者认为,优化TARE with 90Y玻璃微球(参考时间后4天肺叶性注射)应瞄准全非肿瘤肝平均吸收剂量:基线胆红素高于1.1 mg/dL者为50 Gy,低于1.1 mg/dL者为90 Gy。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Transarterial radioembolization (TARE) is, by all standards, a radiation therapy. As such, according to Euratom Directive 2013/59, it should be optimized by a thorough treatment plan based on the distinct evaluation of absorbed dose to the lesions and to the non-tumoural liver (two-compartment dosimetry). Since the dosimetric prediction with 99mTc albumin macro-aggregates (MAA) of non-tumoural liver is much more accurate than the same prediction on lesions, treatment planning should focus on non-tumoural liver rather than on lesion dosimetry. The aim of this study was to determine a safety limit through the analysis of pre-treatment dosimetry with 99mTc-MAA single photon emission computed tomography (SPECT/CT), in order to deliver the maximum tolerable absorbed dose to non-tumoural liver. METHODS: Data from intermediate/advanced hepato-cellular carcinoma (HCC) patients treated with 90Y glass microspheres were collected in this single-arm retrospective study. Injection was always lobar, even in case of bilobar disease, to avoid treating the whole liver in a single session. A three-level definition of liver decompensation (LD) was introduced, considering toxicity only in cases of liver decompensation requiring medical action (LD type C, LDC). We report LDC rates, receiver operating characteristic (ROC) analysis between LDC and NO LDC absorbed dose distributions, normal tissue complication probability (NTCP) curves and uni- and multivariate analysis of risk factors associated with toxicity. RESULTS: A 6-month timeline was defined as necessary to capture all treatment-related toxicity events. Previous transarterial chemoembolization (TACE), presence or extension of portal vein tumoural thrombosis (PVTT) and tumour pattern (nodular versus infiltrative) were not associated with tolerance to TARE. On the contrary, at the multivariate analysis, the absorbed dose averaged over the whole non-tumoural liver (including the non-injected lobe) was a prognostic indicator correlated with liver decompensation (odds ratio = 4.24). Basal bilirubin > 1.1 mg/dL was a second even more significant risk factor (odds ratio = 6.35). NTCP analysis stratified with this bilirubin cut-off determined a 15% liver decompensation risk at 50 Gy/90 Gy for bilirubin >/< 1.1 mg/dL. These results are valid for a 90Y glass microsphere administration 4 days after the reference time. CONCLUSION: Given the low predictive accuracy of 99mTc-MAA on lesion absorbed dose reported by several authors, an optimized TARE with 90Y glass microspheres with lobar injection 4 days after reference time should aim at an absorbed dose averaged over the whole non-tumoural liver of 50 Gy/90 Gy for basal bilirubin higher/lower than 1.1 mg/dL, respectively.
引用
- Chiesa C, Mira M, Bhoori S, et al. Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020. PMID: 32451604. doi:10.1007/s00259-020-04845-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。